Carvedilol (versus unexposed) updated on 12-17-2024

Caesarean

id	Study   Auto Kubota - Carvedilol, 2023Tanaka, 2016	Lib. in paper	Exposition period  Auto during pregnancy (anytime or not specified)1st trimester2nd trimester3rd trimester2nd and/or 3rd trimesterthroughout pregnancyearly pregnancydays before deliverylate pregnancypreconception-onlypericonceptionalpreconceptional for kinetic reasonat least 1st trimester3 months (or more) before pregnancy or during pregnancy1st and 2nd trimester3 months or more before pregnancy or1st trimester	Study type  All studies Case control excluded Only case control	Control type    Auto unexposed (general population or NOS)unexposed, sickunexposed, disease freeexposed to other treatment, sicknot specifiedsiblingwhatever (meta-analysis)	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S17236 R72136	Kubota - Carvedilol, 2023	Cesarean	during pregnancy (anytime or not specified)	retrospective cohort	unexposed, sick	Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...)	13.80 [3.23;58.91] C	30/32   137/263	167	32		ref
S14076 R55410	Tanaka, 2016	Cesarean	during pregnancy (anytime or not specified)	retrospective cohort	unexposed, sick	Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...)	5.96 [1.26;28.27] C	11/13   48/100	59	13		ref
					Total	2 studies	9.34 [3.23;26.99]		226	45
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis

Publication bias and p-hacking diagnosis

Sub-groups analysis using all included studies

excluded